Skip to main content
SYS · ONLINEPASS · 63.0%
Open Assay
Independent Testing / Est. 2026
BATCH04·26·B
PASS63.0%
N27
PeptidesLongevityPQQ

PQQ

/ Pyrroloquinoline quinone (small molecule, redox cofactor); proposed mitochondrial biogenesis inducer
TIER 3 · PreclinicalN = 0 · TESTING PENDINGMW 330.20 g·mol⁻¹

ALIAS · PQQ · Pyrroloquinoline quinone · Methoxatin

Pass rate
0
Samples
0
Suppliers
Research use onlyAny dose figures below describe what specific cited studies used, reported factually. Nothing on this page is guidance for human use.READ FIRST →

Terms in this page you can click for a plain-English popup: , , , , , , , .

§ A · Identity
Primary sequence— sequence not captured —
MW · 330.20CLASS · Pyrroloquinoline quinone (small molecule, redox cofactor); proposed mitochondrial biogenesis inducerCATEGORY · Longevity

Tier 3. PQQ is a redox-active small-molecule quinone cofactor with rodent mitochondrial-biogenesis literature (Stites 2006 and follow-ups) and small human studies of supplementation (Harris 2013 and a handful of Japanese-language studies). Sold as a dietary supplement in the US; the supplement-grade material is the predominant exposure pathway. No FDA-approved therapeutic use.

§ B · Mechanism of action

PQQ is a tricyclic ortho-quinone first identified as a bacterial enzyme cofactor and subsequently characterised as a redox-active small molecule with antioxidant and electron-transfer properties. The mitochondrial-biogenesis hypothesis derives from rodent studies showing that PQQ deprivation reduces mitochondrial number and function and that supplementation increases mitochondrial markers (PGC-1α, NRF1, mitochondrial DNA content) in liver and other tissues. Whether PQQ functions as a true vitamin in mammals — fulfilling a defined enzyme-cofactor role rather than acting as a non-specific antioxidant — has been debated in the cofactor literature.

§ C · Human clinical evidence

Tier 3. Rodent mitochondrial biogenesis literature is the strongest preclinical anchor (Stites 2006; subsequent group follow-ups). Harris 2013 reported a small open-label human study of oral PQQ 20 mg daily for 75 days with effects on inflammatory and metabolic biomarkers. Subsequent small Japanese trials have explored cognitive-function endpoints. No Phase 3 trial; human outcome data are limited.

§ D · Primary literature
PubMed24231099Harris CB et al.Dietary pyrroloquinoline quinone (PQQ) alters indicators of inflammation and mitochondrial-related metabolism in human subjects · Journal of Nutritional Biochemistry · human-phase-1Oral PQQ 0.3 mg/kg/day for 75 days altered inflammatory and mitochondrial-related metabolic markers (urinary metabolomics; plasma CRP) in healthy adults.Limitations: Small open-label single-arm study; biomarker endpoints; n=10.2013
PubMed16424117Stites T et al.Pyrroloquinoline quinone modulates mitochondrial quantity and function in mice · Journal of Nutrition · rodentDietary PQQ deprivation reduced mitochondrial content and function in mice and supplementation restored it; foundational rodent paper for the mitochondrial-biogenesis claim.Limitations: Rodent dietary study; mechanistic pathway from PQQ to PGC-1α elaborated in subsequent group work.2006
§ F · Safety signal

In published small human studies, well tolerated at oral doses up to 20–40 mg daily. The supplement-grade material has decades of consumer exposure without identified major safety signals, though no comprehensive post-marketing safety database is available.

§ H · Regulatory status

Regulatory status

FDA status:
Not FDA-approved
§ I · Notable gaps and controversies

The 'mitochondrial biogenesis' framing is supported by rodent PGC-1α-pathway data but the human disease-modifying-outcome database does not yet support the geroscience claim. Whether PQQ is a vitamin (fulfilling a defined cofactor role) or a non-specific antioxidant remains unresolved in the mammalian biochemistry literature. Supplement-grade PQQ products vary substantially in dosing and formulation; the published academic studies generally use defined research-grade material that consumer product is not always equivalent to.